Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity-Reference-Cited by-同舟云学术

Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity

Published:2019-08-01 Issue:8 Volume:14 Page:e0220189
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Abbà Carlotta,Campanelli Rita,Catarsi Paolo,Villani Laura,Abbonante Vittorio,Sesta Melania Antonietta,Barosi Giovanni,Rosti Vittorio,Massa Margherita^ORCID

Funder

Associazione Italiana per la Ricerca sul Cancro

Fondazione IRCCS Policlinico San Matteo

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference36 articles.

1. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia;G Barosi;Blood,2001

2. Myeloproliferative neoplasms: from origins to outcomes;J Nangalia;Blood,2017

3. JAK/STAT signaling in hematological malignancies;W Vainchenker;Oncogene,2013

4. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera;C James;Nature,2005

5. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia;Y Pikman;PLoS Med,2006

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Mutated Calreticulin in the Pathogenesis of BCR-ABL1-Negative Myeloproliferative Neoplasms;International Journal of Molecular Sciences;2024-09-12

2. Downregulated KLF2 in polycythemia vera and essential thrombocythemia induces prothrombotic gene expression;Blood Advances;2023-03-01

3. STAT5 is Expressed in CD34+/CD38− Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms;Cancers;2020-04-21

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis

;Cancer Management and Research;2019-12